Initial findings on lamotrigine as augmentation strategy in treatment-resistant depression

Drug News and Perspectives

Volumn 19, Issue 7, 2006, Pages 427-430

  McIntyre, Jennifer ^a   Moral, Ma Angels ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; LAMOTRIGINE; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ANTIDEPRESSANT AGENT; TRIAZINE DERIVATIVE;

ARTICLE; BIPOLAR I DISORDER; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; DRUG COMBINATION; DRUG RESISTANCE; MAJOR DEPRESSION; REVIEW;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; TRIAZINES;

EID: 33750519233     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2006.19.7.1044921     Document Type: Article

References (25)

1. Keller, M.B. Issues in treatment-resistant depression. J Clin Psychiatry 2005, 66(Suppl 8): 5-12.
2. Hirschfeld, R.M., Montgomery, S.A., Aguglia, E. et al. Partial response and nonresponse to antidepressant therapy: Current approaches and treatment options. J Clin Psychiatry 2002, 63: 826-37.
3. Thase, M.E. and Rush, A.J. When at first you don't succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997, 58(Suppl 13): 23-9.
4. Thase, M.E. New approaches to managing difficult-to-treat depressions. J Clin Psychiatry 2003, 64(Suppl 1): 3-4.
5. Thase, M.E. Therapeutic alternatives for difficult-to-treat depression: A narrative review of the state of the evidence. CNS Spectr 2004, 9: 808-16, 818-21.
6. Initial results help clinicians identify patients with treament-resistant depression. NIMH Press Release, 1 January 2006 (http://www.nimh.nih.gov/press/ stard.cfm).
7. A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder. ClinicalTrials.gov. Study Identifier NCT00095758.
8. Olanzapine Augmentation Therapy in Treatment-Resistant Depression: A Double-Blind Placebo-Controlled Trial. Clinical Trials.gov. Study Identifier NCT00273624.
9. Ropinirole CR as an Adjunctive Agent in the Treatment of Major Depression. Clinical Trials.gov. Study Identifier NCT00285727.
10. CONCERTA(R) (Methylphenidate Hydrochloride) as Add-on Therapy in the Treatment of Adult Major Depressive Disorder. ClinicalTrials.gov. Study Identifier NCT00246233.
11. GlaxoSmithKline. Lamictal: First medication since Lithium approved for long-term maintenance treatment of bipolar disorder. Press Release (2003, June 23).
12. Pappagallo, M. Newer antiepileptic drugs: Possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003, 25: 2506-38.
13. Backonja, M. Neuromodulating drugs for the symptomatic treatment of neuropathic pain. Curr Pain Headache Rep 2004, 8: 212-6.
14. Barbee, J.G. and Jambour, N.J. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 2002, 63: 737-41.
15. Rocha, F.L. and Hara, C. Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol 2003, 18: 97-9.
16. Gutierrez, R.L., McKercher, R., Galea, J. et al. Lamotrigine augmentation strategy for patients with treatment-resistant depression. CNS Spectr 2005, 10: 800-5.
17. Barbosa, L., Berk, M. and Vorster, M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003, 64: 403-7.
18. Schindler, F., Anghelescu, I. et al. The LILA-Study: An observational study comparing the efficacy of lithium vs lamotrigine as an augmentation strategy for treatment-resistant depression (TRD). 59th Annu Meet Soc Biol Psychiatry (SOBP) (Apr 29 to May 1, New York) 2004, Abst 140.
19. Baloescu, A., Grigorescu, G. and Gheorghe, M.D. Lamotrigine in the treatment of resistant depression. 14th Assoc Eur sychiatr Congr (March 4-8, Nice) 2006, Abst 093.
20. Southam, E., Pereira, R., Stratton, S.C. et al. Effect of lamotrigine on the activities of monoamine oxidases A and B in vitro and on monoamine disposition in vivo. Eur J Pharmacol 2005, 519: 237-45.
21. Bourin, M., Masse, F. and Hascoet, M. Evidence for the activity of lamotrigne at 5-HT1A receptors in the mouse forced swimming test. J Psychiatry Neurosci 2005. 30: 275-82.
22. Vinod, K.Y. et al. Lamotrigine induced selective changes in 5-HT1A receptor mediated response in rat brain. Neurochem Int 2002, 40: 315-9.
23. Rabiner, E.A. et al. Preferential 5-HT1A autoreceptor occupancy by pindolol is attenuated in depressed patients: Effect of treatment of an endophenotype of depression. Neuropsychopharmacology 2004, 29: 1688-98.
24. Sim-Selley, L.J. et al. Region-specific changes in 5-HT1A receptor-activated G-proteins in rat brain following chronic buspirone. Eur J Pharmacol 2000, 389: 147-53.
25. Redrobe, J.P. et al. The effect of lithium administration in animal models of depression: A short review. Fundam Clin Pharmacol 1999, 13:293-9.